---
layout: default
title: Fulvestrant
parent: 僅模型預測 (L5)
nav_order: 64
evidence_level: L5
indication_count: 10
---

# Fulvestrant
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

Using the `txgnn-pipeline` skill to confirm context — this is a TW (Taiwan) deployment report. Now generating the evaluation report from the Evidence Pack.

---

# Fulvestrant: From ER+ Breast Cancer to HIV Infectious Disease

## One-Sentence Summary

Fulvestrant (Faslodex) is an internationally established selective estrogen receptor degrader (SERD), widely used for hormone receptor-positive (HR+) advanced breast cancer — though it holds no registered approval in Taiwan.
The TxGNN model predicts it may have activity against **HIV Infectious Disease**,
with **0 clinical trials** and **1 indirectly related publication** currently available to support this direction.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | ER+ advanced breast cancer (internationally approved; not registered in Taiwan) |
| Predicted New Indication | HIV Infectious Disease |
| TxGNN Prediction Score | 99.91% |
| Evidence Level | L5 |
| Taiwan Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this dataset. Based on known information, Fulvestrant is a SERD (Selective Estrogen Receptor Degrader) — it binds to, blocks, and promotes degradation of the estrogen receptor (ER), effectively silencing estrogen signaling. Its efficacy in ER+ advanced breast cancer has been demonstrated across multiple international Phase 3 trials, and it is approved in countries including the United States, EU, and Japan under the brand name Faslodex.

The theoretical rationale connecting Fulvestrant to HIV infectious disease runs through immune modulation: estrogen receptors are expressed on CD4+ T lymphocytes and macrophages — the very cell types that HIV infects and depletes. Modulating ER signaling could, in principle, alter the immune microenvironment in which HIV replicates. Sex-based differences in HIV disease progression and immune response are well documented, suggesting a biological role for sex hormones in HIV pathophysiology.

However, the only available supporting publication (PMID 40343334) investigates **HTLV-1-associated myelopathy (HAM)** — a neuroinflammatory disease caused by a retrovirus from an entirely different family than HIV. The biological extrapolation from HTLV-1 to HIV is scientifically tenuous. No study has directly examined the effect of Fulvestrant or any SERD in HIV infection, whether in vitro, in animal models, or in humans. The TxGNN prediction likely reflects shared graph topology between ER signaling and immune pathways rather than disease-specific mechanistic evidence.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for Fulvestrant in HIV infectious disease.

---

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|------|------|---------|-------------|
| [40343334](https://pubmed.ncbi.nlm.nih.gov/40343334/) | 2025 | Multi-cohort Cross-omics Analysis | Research Square (Preprint) | Systems biology analysis of HTLV-1-associated myelopathy (HAM) — explores (epi)genomic disease mechanisms and potential therapeutic targets in a neglected retroviral neuroinflammatory disorder affecting predominantly women; Fulvestrant's relevance to HIV is indirect and not directly examined |

---

## Taiwan Market Information

Fulvestrant is not registered in Taiwan. No product authorizations are on file with the TFDA, and no approved indications are available for local reference.

---

## Cytotoxicity

| Item | Content |
|------|---------|
| Cytotoxicity Classification | Targeted therapy — Hormonal/Endocrine (SERD: Selective Estrogen Receptor Degrader) |
| Myelosuppression Risk | Low (SERDs do not cause significant bone marrow suppression; not a conventional cytotoxic agent) |
| Emetogenicity Classification | Low |
| Monitoring Items | Liver function tests (LFTs), injection site reactions (IM injection formulation), bone mineral density (long-term use), signs of hepatotoxicity |
| Handling Protection | Follow institutional antineoplastic injectable drug handling protocols; standard cytostatic precautions apply |

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
There is no direct clinical or preclinical evidence supporting Fulvestrant's efficacy in HIV infectious disease. The sole available publication addresses HTLV-1 — a distinct retrovirus — making the biological extrapolation to HIV unreliable. With L5 evidence (model prediction only), this indication is not ready for further translational investment at this time.

**To proceed, the following is needed:**
- In vitro studies assessing ER modulation effects on HIV replication in CD4+ T cells and macrophages (establish proof-of-concept)
- Preclinical HIV animal model data (e.g., humanized mouse or NHP models)
- Mechanistic clarification of the ER–HIV replication interaction pathway
- Detailed MOA and safety data retrieved from DrugBank and the TFDA package insert (both currently absent from this dataset)
- Assessment of whether IM depot administration (Fulvestrant's only available route) is compatible with HIV treatment settings
---

